Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation

Area of Science:

• Cardiovascular Physiology
• Neuroendocrinology

Background:

• Chronic heart failure (HF) involves sympathetic hyperactivity, marked by elevated catecholamines (CAs).
• This hyperactivity significantly contributes to HF morbidity and mortality.
• Current research focuses on sympatholytic treatments to mitigate sympathetic overactivity.

Purpose of the Study:

• To review recent advances in understanding adrenal adrenoceptors (ARs) in regulating sympathetic outflow in HF.
• To discuss the regulatory mechanisms of ARs, including their interaction with G-protein-coupled receptor kinases (GRKs).
• To explore the therapeutic potential and challenges of targeting adrenal ARs for HF treatment.

Main Methods:

• Review of recent scientific literature on adrenal adrenoceptors and sympathetic nervous system regulation in heart failure.
• Discussion of the roles of alpha(2)-adrenoceptors (inhibitory) and beta-adrenoceptors (stimulatory) in catecholamine secretion.
• Analysis of G-protein-coupled receptor kinase (GRK) regulation of adrenoceptor signaling.

Main Results:

• Adrenal ARs play a critical role in modulating sympathetic outflow.
• Alpha(2)ARs inhibit, while betaARs enhance catecholamine secretion from the adrenal gland.
• GRKs are key regulators of AR signaling and function.

Conclusions:

• Adrenal ARs represent a promising target for novel sympatholytic therapies in HF.
• Understanding AR regulation by GRKs is crucial for developing effective treatments.
• Harnessing adrenal AR function presents both significant potential benefits and challenges for HF management.